Our investigational drug candidate, nelotanserin, is a selective inverse agonist of the 5HT2A receptor.i*

Intepirdine is an orally administered, potent antagonist of the 5HT6 receptor. This receptor is expressed almost exclusively within the central nervous system, and blocking the 5HT6 receptor promotes the release of acetylcholine in the brain.i


  1. Ramirez MJ. 5-HT6 receptors and Alzheimer's disease. Alzheimer Res Ther. 2013;5(2):15. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706851/. Published April 22, 2013. Accessed August 16, 2017.